Armstrong AJ - Search Results

1

Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer.

Ware KE, Garcia-Blanco MA, Armstrong AJ, Dehm SM. Ware KE, et al. Among authors: armstrong aj. Endocr Relat Cancer. 2014 Aug;21(4):T87-T103. doi: 10.1530/ERC-13-0470. Epub 2014 May 23. Endocr Relat Cancer. 2014. PMID: 24859991 Free PMC article. Review.

2

Clinical endpoints for drug development in prostate cancer.

Ramiah V, George DJ, Armstrong AJ. Ramiah V, et al. Among authors: armstrong aj. Curr Opin Urol. 2008 May;18(3):303-8. doi: 10.1097/MOU.0b013e3282fb7807. Curr Opin Urol. 2008. PMID: 18382240 Review.

3

Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.

Armstrong AJ, Febbo PG. Armstrong AJ, et al. Oncologist. 2009 Aug;14(8):816-27. doi: 10.1634/theoncologist.2009-0043. Epub 2009 Aug 14. Oncologist. 2009. PMID: 19684076 Free article. Review.

4

Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer.

Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M. Armstrong AJ, et al. Clin Cancer Res. 2010 Jan 1;16(1):203-11. doi: 10.1158/1078-0432.CCR-09-2514. Epub 2009 Dec 15. Clin Cancer Res. 2010. PMID: 20008841

5

Epithelial-mesenchymal transition in prostate cancer: providing new targets for therapy.

Armstrong AJ, Freedland SJ, Garcia-Blanco M. Armstrong AJ, et al. Asian J Androl. 2011 Mar;13(2):179-80. doi: 10.1038/aja.2010.169. Epub 2011 Jan 3. Asian J Androl. 2011. PMID: 21383677 Free PMC article. No abstract available.

6

Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers.

Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, Herold CI, Marcom PK, George DJ, Garcia-Blanco MA. Armstrong AJ, et al. Mol Cancer Res. 2011 Aug;9(8):997-1007. doi: 10.1158/1541-7786.MCR-10-0490. Epub 2011 Jun 10. Mol Cancer Res. 2011. PMID: 21665936 Free PMC article.

7

Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.

Armstrong AJ, Eisenberger MA, Halabi S, Oudard S, Nanus DM, Petrylak DP, Sartor AO, Scher HI. Armstrong AJ, et al. Eur Urol. 2012 Mar;61(3):549-59. doi: 10.1016/j.eururo.2011.11.009. Epub 2011 Nov 12. Eur Urol. 2012. PMID: 22099611 Free PMC article. Review.

8

The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer.

Armstrong AJ, Ferrari AC, Quinn DI. Armstrong AJ, et al. Clin Adv Hematol Oncol. 2011 Dec;9(12 Suppl 28):1-14; quiz 15-6. Clin Adv Hematol Oncol. 2011. PMID: 22407145 Review.

9

Potential predictive biomarkers for individualizing treatment for men with castration-resistant prostate cancer.

Bitting RL, Armstrong AJ. Bitting RL, et al. Among authors: armstrong aj. Cancer J. 2013 Jan-Feb;19(1):25-33. doi: 10.1097/PPO.0b013e31827e0b9c. Cancer J. 2013. PMID: 23337754 Review.

10

Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.

Bitting RL, Armstrong AJ. Bitting RL, et al. Among authors: armstrong aj. Endocr Relat Cancer. 2013 May 20;20(3):R83-99. doi: 10.1530/ERC-12-0394. Print 2013 Jun. Endocr Relat Cancer. 2013. PMID: 23456430 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

388 results

Search Page

Filters